Gilteritinib (BioDeep_00000179411)

   

human metabolite blood metabolite


代谢物信息卡片


6-Ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-2-pyrazinecarboxamide

化学式: C29H44N8O3 (552.3536194)
中文名称: 吉瑞替尼
谱图信息: 最多检出来源 Mus musculus(blood) 40%

分子结构信息

SMILES: CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5
InChI: InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

同义名列表

11 个代谢物同义名

6-Ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-2-pyrazinecarboxamide; 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide; 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(oxan-4-ylamino)pyrazine-2-carboxamide; 6-Ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide; ASP-2215asp2215; Gilteritinibum; Gilteritinib; ASP-2215; ASP 2215; ASP2215; Xospata



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Aysha S Ansari, Remant K C, Luis C Morales, Mohammad Nasrullah, Daniel Nisakar Meenakshi Sundaram, Cezary Kucharski, Xiaoyan Jiang, Joseph Brandwein, Hasan Uludağ. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models. Journal of controlled release : official journal of the Controlled Release Society. 2024 Mar; 367(?):821-836. doi: 10.1016/j.jconrel.2024.02.018. [PMID: 38360178]
  • Mengyu Zhang, Soichiro Tajima, Kimitaka Suetsugu, Takeshi Hirota, Yuichi Tsuchiya, Takuji Yamauchi, Goichi Yoshimoto, Toshihiro Miyamoto, Nobuaki Egashira, Koichi Akashi, Ichiro Ieiri. Development and Validation of an LC-MS/MS Method to Quantify Gilteritinib and Its Clinical Application in Patients With FLT3 Mutation-Positive Acute Myelogenous Leukemia. Therapeutic drug monitoring. 2022 Aug; 44(4):592-596. doi: 10.1097/ftd.0000000000000971. [PMID: 35149666]
  • Daria Zdżalik-Bielecka, Kamila Kozik, Agata Poświata, Kamil Jastrzębski, Marta Jakubik, Marta Miączyńska. Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner. Molecular cancer research : MCR. 2022 Mar; 20(3):446-455. doi: 10.1158/1541-7786.mcr-21-0444. [PMID: 34782372]
  • Hiroto Kataoka, Tetsuya Saita, Asuki Oka, Momoka Yamada, Masashi Shin. An Indirect Competitive Enzyme-Linked Immunosorbent Assay for the Determination of Brigatinib and Gilteritinib Using a Specific Polyclonal Antibody. Biological & pharmaceutical bulletin. 2022; 45(7):904-909. doi: 10.1248/bpb.b22-00166. [PMID: 35786598]
  • Pierre-Yves Dumas, Arnaud Villacreces, Amélie V Guitart, Ali El-Habhab, Layal Massara, Olivier Mansier, Audrey Bidet, Delphine Martineau, Solene Fernandez, Thibaut Leguay, Arnaud Pigneux, Isabelle Vigon, Jean-Max Pasquet, Vanessa Desplat. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 11; 27(21):6012-6025. doi: 10.1158/1078-0432.ccr-20-3114. [PMID: 34400415]
  • Dominique A Garrison, Yan Jin, Muhammad Erfan Uddin, Alex Sparreboom, Sharyn D Baker. Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2021 Aug; 1179(?):122882. doi: 10.1016/j.jchromb.2021.122882. [PMID: 34365291]
  • Eris Tollkuci, Tiffany Tran, Rebecca Myers. Gilteritinib administration in a hemodialysis patient. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2021 Jul; 27(5):1255-1257. doi: 10.1177/1078155220973259. [PMID: 33175659]
  • Takeo Yasu, Tomiyuki Sugi, Kenji Momo, Masao Hagihara, Hiroshi Yasui. Determination of the concentration of gilteritinib in human plasma using HPLC. Biomedical chromatography : BMC. 2021 Apr; 35(4):e5028. doi: 10.1002/bmc.5028. [PMID: 33179270]
  • Masamichi Mori, Kazuyuki Hidaka. [Pharmacological and clinical profile of gilteritinib (Xospata® tablets 40 mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 2021; 156(1):37-46. doi: 10.1254/fpj.20050. [PMID: 33390479]
  • Angela Joubert James, Catherine C Smith, Mark Litzow, Alexander E Perl, Jessica K Altman, Dale Shepard, Takeshi Kadokura, Kinya Souda, Melanie Patton, Zheng Lu, Chaofeng Liu, Selina Moy, Mark J Levis, Erkut Bahceci. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clinical pharmacokinetics. 2020 10; 59(10):1273-1290. doi: 10.1007/s40262-020-00888-w. [PMID: 32304015]
  • Andrew J Wilson, Ethan Troy-Barnes, Maryam Subhan, Fiona Clark, Rajeev Gupta, Adele K Fielding, Panagiotis Kottaridis, Marc R Mansour, Jenny O'Nions, Elspeth Payne, Naina Chavda, Robert Baker, Kirsty Thomson, Asim Khwaja. Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19. British journal of haematology. 2020 08; 190(4):e189-e191. doi: 10.1111/bjh.16962. [PMID: 32584418]
  • Qiong Wang, Zhe Chen, Dingwen Chen, Xia-Yan Ye. An LC-MS/MS Bioanalytical Assay for the Determination of Gilteritinib in Rat Plasma and Application to a Drug-Drug Interaction Study. Drug design, development and therapy. 2020; 14(?):2061-2067. doi: 10.2147/dddt.s243760. [PMID: 32546970]
  • Alexander E Perl, Jessica K Altman, Jorge Cortes, Catherine Smith, Mark Litzow, Maria R Baer, David Claxton, Harry P Erba, Stan Gill, Stuart Goldberg, Joseph G Jurcic, Richard A Larson, Chaofeng Liu, Ellen Ritchie, Gary Schiller, Alexander I Spira, Stephen A Strickland, Raoul Tibes, Celalettin Ustun, Eunice S Wang, Robert Stuart, Christoph Röllig, Andreas Neubauer, Giovanni Martinelli, Erkut Bahceci, Mark Levis. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. The Lancet. Oncology. 2017 08; 18(8):1061-1075. doi: 10.1016/s1470-2045(17)30416-3. [PMID: 28645776]